2022
- ALA-1000 received notice of patent allowance from National Institute of Industrial Property Institute (INAPI), Chile on August 10, Application No. 624-2019
- ALA-1000 received notice of patent allowance from European Patent Office (EPO) on May 12 , Application No. 17850245.6
- ALA-1000 received notice of patent allowance from Director de Invenciones y Nuevas Tecnologías INDECOPI on May 12, Application No. 000487-2019/DIN
- ALA-1000 received notice of patent allowance from Intellectual Property Office of India on May 6, Application No. 201947006642
- ALA-1000 received notice of patent allowance from Intellectual Property Office of Singapore (IPOS) on April 21, Application No. 11201901294Q
- Alar announces Significant Progress on Developing long-acting Buprenorphine
Injectable ALA-1000 on January 13
2021
- ALA-1000 received notice of patent allowance from Directorate General of Intellectual Property (DGIP) of Indonesia on November 30, Application No. P00201902139
- Alar announced results from ALA-1000 Single Ascending Dose Study in Opioid Dependent Patients on November 9
- ALA-1000 received notice of patent allowance from Intellectual Property Office of Vietnam on October 29, Application No. 1-2019-01258
- Successful End-of-Phase 2 Meeting with US FDA for ALA-1000 for the Treatment of Opioid Use Disorder on October 28
- ALA-1000 received notice of patent allowance from Taiwan Intellectual Property Office (TIPO) on September 3, Application No. 106131215
- ALA-1000 received notice of patent allowance from South Africa-Companies and Intellectual Property Commission Department of Trade and Industry (CIPC) on August 25, Application No. 201900890
- ALA-1000 received notice of patent allowance from Japan Patent Office (JPO) on August 3, Application No. 特願2019-535434
- ALA-1000 received notice of patent allowance from Innovation, Science and Economic Development Canada (ISED) on May 10, Application No.3,033,046
- ALA-1000 received notice of patent allowance from the IP New Zealand on April 30. Patent No. 750367
- ALA-1000 received notice of allowance for patent registration from Korean Intellectual Property Office on April 16 (Application No. 10-2019-7009185)
- ALA-1000 received Decision of Grant from Federal Service for Intellectual Property (ROSPATENT) on April 12 (Application No. 2019102895)
2020
- Listed on Taipei Exchange Market in Taiwan on September 23. Traded on October 5
- ALA-1000 received notice of patent allowance from the IP Australia
- ALA-3000 completed pre-IND Meeting with US FDA
- ALA-1000 received notice of patent allowance from the Mexican Institute of Industrial Property (IMPI)
- Approved to be a public offering company on June 3. Stock Code: 6785
- ALA-1000 received notice of patent allowance from USPTO
- ALA-1000 was approved by Ministry of Economic Affairs : A+ Industrial Innovation R&D Program (fast track)
2019
Approved by the Ministry of Economic Affairs as a Biotech Pharmaceutical company
ALA-1000 received US FDA IND approval
Approved to be located in Central Science Park
2017
- ALA-1000 was approved by Ministry of Economic Affairs：A+ Industrial Innovation R&D Program－Industrial Technology Foresight Research Program
2016
- Alar Pharmaceuticals Inc. was founded